Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23111969 | 0.89 | MEN1 (0.54) | LMNAHPGDMEN1KMT2A | |
| SCHEMBL23112022 | 0.85 | LMNA (0.64) | LMNAHPGDMEN1KMT2A | |
| SCHEMBL23112086 | 0.78 | KDM1A (0.46) | MAOBLMNAHPGDKDM1AMAOA | |
| SCHEMBL30765211 | 0.78 | KDM1A (0.46) | MAOBLMNAHPGDKDM1AMAOA | |
| SCHEMBL15969027 | 0.77 | MEN1 (0.63) | LMNAHPGDMEN1KMT2A | |
| SCHEMBL18993390 | 0.76 | KDM4E (0.69) | PARP10KDM4ELMNAHPGDMEN1 | |
| SCHEMBL2744895 | 0.75 | PARP10 (0.59) | PARP10MAOBLMNAHPGD | |
| SCHEMBL25922476 | 0.75 | GLRA1 (0.63) | KDM4EMAOBLMNAHPGDKDM1A | |
| SCHEMBL25366114 | 0.75 | KDM1A (0.47) | MAOBLMNAHPGDKDM1AMAOA | |
| SCHEMBL6036178 | 0.74 | KDM1A (0.51) | KDM4EMAOBLMNAKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-03-20 | — | — | US | disclosed |
| CN-112424181-B | Substituted condensed thiophenes as STING modulators | 希泰克斯特私人有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-11613525-B2 | Substituted condensed thiophenes as modulators of sting | CTXT PTY LIMITED (AU) | 2023-03-28 | — | — | US | disclosed |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD. (AU) | 2021-07-15 | — | — | US | disclosed |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD. (AU) | 2021-07-15 | — | — | US | disclosed |
| EP-3793988-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | Ctxt Pty Ltd (AU) | 2021-03-24 | — | — | EP | disclosed |
| CN-112424181-A | Substituted condensed thiophenes as STING modulators | 希泰克斯特私人有限公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | PARP10 2170/4885KDM4E 1469/4885STING1 1/4885 |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | PARP10 2493/4885KDM4E 1519/4885STING1 1/4885 |
| US-11613525-B2 | Substituted condensed thiophenes as modulators of sting | STING1, CGAS, IRF3 | PARP10 2493/4885KDM4E 1519/4885STING1 1/4885 |
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | PARP10 2170/4885KDM4E 1469/4885STING1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.